CA2794958A1 - Injectable drug delivery formulation - Google Patents

Injectable drug delivery formulation Download PDF

Info

Publication number
CA2794958A1
CA2794958A1 CA2794958A CA2794958A CA2794958A1 CA 2794958 A1 CA2794958 A1 CA 2794958A1 CA 2794958 A CA2794958 A CA 2794958A CA 2794958 A CA2794958 A CA 2794958A CA 2794958 A1 CA2794958 A1 CA 2794958A1
Authority
CA
Canada
Prior art keywords
formulation
active agent
groups
group
solvent system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2794958A
Other languages
English (en)
French (fr)
Inventor
Joram Slager
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Surmodics Inc
Original Assignee
Surmodics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Surmodics Inc filed Critical Surmodics Inc
Publication of CA2794958A1 publication Critical patent/CA2794958A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B30/00—Preparation of starch, degraded or non-chemically modified starch, amylose, or amylopectin
    • C08B30/12—Degraded, destructured or non-chemically modified starch, e.g. mechanically, enzymatically or by irradiation; Bleaching of starch
    • C08B30/18—Dextrin, e.g. yellow canari, white dextrin, amylodextrin or maltodextrin; Methods of depolymerisation, e.g. by irradiation or mechanically
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B31/00—Preparation of derivatives of starch
    • C08B31/003—Crosslinking of starch
    • C08B31/006—Crosslinking of derivatives of starch
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
    • C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
    • C08J3/075—Macromolecular gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2794958A 2010-03-29 2011-03-29 Injectable drug delivery formulation Abandoned CA2794958A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31871710P 2010-03-29 2010-03-29
US61/318,717 2010-03-29
PCT/US2011/030271 WO2011123416A1 (en) 2010-03-29 2011-03-29 Injectable drug delivery formulation

Publications (1)

Publication Number Publication Date
CA2794958A1 true CA2794958A1 (en) 2011-10-06

Family

ID=44246149

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2794958A Abandoned CA2794958A1 (en) 2010-03-29 2011-03-29 Injectable drug delivery formulation

Country Status (5)

Country Link
US (1) US8697105B2 (enExample)
EP (1) EP2552969A1 (enExample)
JP (1) JP2013523748A (enExample)
CA (1) CA2794958A1 (enExample)
WO (1) WO2011123416A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697105B2 (en) 2010-03-29 2014-04-15 Surmodics, Inc. Injectable drug delivery formulation
CN109200013A (zh) * 2011-12-05 2019-01-15 因赛普特有限责任公司 医用有机凝胶方法和组合物
WO2016100861A1 (en) * 2014-12-19 2016-06-23 Baxter International, Inc. Flowable hemostatic composition
AU2020340441A1 (en) * 2019-08-29 2022-03-24 Paul Douglas Godfrin Hydrogels as oral delivery dosage forms, methods of making and using same
CN112569179B (zh) * 2020-12-25 2022-12-27 上海交通大学医学院附属第九人民医院 一种可注射水凝胶体系及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
DK89592D0 (da) * 1992-07-07 1992-07-07 Helle Broendsted Laegemiddelafgivelsesindretning samt fremgangsmaade til fremstilling deraf
US6884842B2 (en) * 1997-10-14 2005-04-26 Alnis Biosciences, Inc. Molecular compounds having complementary surfaces to targets
IL155866A0 (en) * 2003-05-12 2003-12-23 Yissum Res Dev Co Responsive polymeric system
US20070065483A1 (en) 2005-09-21 2007-03-22 Chudzik Stephen J In vivo formed matrices including natural biodegradable polysaccharides and uses thereof
JP2009529967A (ja) 2006-03-15 2009-08-27 サーモディクス，インコーポレイティド 天然生分解性ポリサッカライドの疎水性誘導体及びそれらの使用
US7638344B2 (en) 2006-06-28 2009-12-29 Surmodics, Inc. Active agent eluting matrices with particulates
JP5694664B2 (ja) 2006-09-29 2015-04-01 サーモディクス，インコーポレイティド 生分解性眼用インプラント及び眼の病気を治療する方法
US20080220047A1 (en) * 2007-03-05 2008-09-11 Sawhney Amarpreet S Low-swelling biocompatible hydrogels
US20090022805A1 (en) 2007-06-28 2009-01-22 Joram Slager Polypeptide microparticles having sustained release characteristics, methods and uses
EP2185637B1 (en) * 2007-09-19 2013-04-03 SurModics, Inc. Biocompatible foams, systems, and methods
US8790701B2 (en) 2008-04-28 2014-07-29 Surmodics, Inc. Poly-α(1→4)glucopyranose-based matrices with hydrazide crosslinking
CA2741415A1 (en) 2008-10-22 2010-04-29 Surmodics, Inc. Swellable biodegradable polymeric matrices and methods
CA2763522A1 (en) 2009-06-02 2010-12-09 Surmodics, Inc. Silane-functionalized hydrophobic .alpha.(1.fwdarw.-4)glucopyranose polymers and polymeric matrices for implantation or injection
US20100302403A1 (en) 2009-06-02 2010-12-02 Raytheon Company Generating Images With Different Fields Of View
US8697105B2 (en) 2010-03-29 2014-04-15 Surmodics, Inc. Injectable drug delivery formulation

Also Published As

Publication number Publication date
WO2011123416A1 (en) 2011-10-06
JP2013523748A (ja) 2013-06-17
US20110236454A1 (en) 2011-09-29
US8697105B2 (en) 2014-04-15
EP2552969A1 (en) 2013-02-06

Similar Documents

Publication Publication Date Title
Jiang et al. Progress on ocular siRNA gene‐silencing therapy and drug delivery systems
US8039010B2 (en) Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
CA2685522C (en) High viscosity macromolecular compositions for treating ocular conditions
US8586556B2 (en) Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules
US20110229457A1 (en) Injectable drug delivery system
US20090226531A1 (en) Methods and composition for intraocular delivery of therapeutic sirna
US20090258924A1 (en) METHODS, COMPOSITIONS AND DRUG DELIVERY SYSTEMS FOR INTRAOCULAR DELIVERY OF siRNA MOLECULES
CN109072241A (zh) 具有改善的玻璃体内半衰期的组合物及其用途
JP2007535536A (ja) 高分子含有持続放出眼内インプラントおよび関連方法
US8697105B2 (en) Injectable drug delivery formulation
Bisen et al. A review on polymers in ocular drug delivery systems
KR102435274B1 (ko) 약물전달시스템으로서의 안구 주입형 마이크로젤 및 이를 포함하는 하이드로젤
Biswas et al. Polymers and their engineered analogues for ocular drug delivery: enhancing therapeutic precision
Sabbagh et al. Hydrogel-based ocular drug delivery systems
US9480646B2 (en) Sustained release siRNA for ocular drug delivery
JP2013523748A5 (enExample)
Sha et al. In situ gels: The next new frontier in ophthalmic drug delivery system
Bhanu Malhotra et al. Ocular drug delivery systems.
US12233157B1 (en) Hydrogel formulations and methods and devices for administration of the same
US20150141484A1 (en) Methods, Compositions and Drug Delivery Systems for Intraocular Delivery of siRNA Molecules
WO2026024285A1 (en) Hydrogel formulations and methods and devices for administration of the same
Villanueva et al. Overcoming Barriers: Controlled-Release Systems as Vectors, the Posterior Segment of the Eye Approach as a Model
Yu Engineering Ocular Drug Delivery System for Posterior Eye Diseases
CA3183343A1 (en) Biodegradable compositions and implants

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20160330